Efficacy of differential non-invasive approaches in determining the clinical course in patients with Crohn’s disease

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-29.10.1056/NEJMra020831Search in Google Scholar

2. Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterol. 2004; 126: 1533-49.10.1053/j.gastro.2004.01.061Open DOISearch in Google Scholar

3. Venkatakrishnan L, Thakaran A, Francis J, Ramesh GN, Philip M, Augustine P. Crohn’s disease-analysis of 26 cases. Indian J Gastroenterol. 1995; 14:A58.Search in Google Scholar

4. Pai CG, Khandige GK. Is Crohn’s disease rare in India? Indian J Gastroenterol. 2000; 19:17-20.Search in Google Scholar

5. Amarapurkar D, Patel N. Crohn’s disease in India. Gastroenterol Today. 2002; 6:73-5.Search in Google Scholar

6. Tan CC, Kang JY, Guan R. Inflammatory bowel disease: an uncommon problem in Singapore. J Gastroenterol Hepatol. 1992, 7:360-2.10.1111/j.1440-1746.1992.tb00997.xOpen DOISearch in Google Scholar

7. Thien-Htut Kudva MV. Ulcerative colitis in Malaysians: a review of 23 patients. Singapore Med. 1989; 30:385-7.Search in Google Scholar

8. Lai CL, Wu PC, Wong KL, et al. Clinical features of ulcerative proctocolitis in Hong Kong Chinese: a review of three decades. Am J Proctol Gastroenterol Colon Rectal Surg. 1985; 1:14-9.Search in Google Scholar

9. Ouyang Q, Tandon R, Goh KL, et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005; 21:408-13.Search in Google Scholar

10. Loftus EV. Clinical epidemiology of inflammatory bowel disease.Gastroenterology. 2004; 126:1504-17.10.1053/j.gastro.2004.01.063Open DOISearch in Google Scholar

11. Makharia GK. Rising incidence and prevalence of Crohn’s disease in Asia: is it apparent or real?. J Gastroenterol Hepatol. 2006; 21:1009-15.10.1111/j.1440-1746.2006.04471.xOpen DOISearch in Google Scholar

12. Jiang XL, Cui HF. An analysis of 10 218 ulcerative colitis cases in China. World J Gastroenterol. 2002; 8:158-61.10.3748/wjg.v8.i1.158Search in Google Scholar

13. Jiang L, Xia B, Li J, et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis. 2006; 12:212-7.10.1097/01.MIB.0000201098.26450.aeOpen DOISearch in Google Scholar

14. Yang SK, Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the SongpaKangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol. 2000; 15:1037-42.10.1046/j.1440-1746.2000.02252.xOpen DOISearch in Google Scholar

15. Lee YM, Fock KM, See SJ, et al: Racial differences in the prevalenceof ulcerative colitis and Crohn’s disease in Singapore. J Gastroenterol Hepatol. 2000; 15:622-5.10.1046/j.1440-1746.2000.02212.xOpen DOISearch in Google Scholar

16. Makharia GK, Tandon RK. Emergence of Celiac Disease and Crohn’s Disease in India. Medicine Update. 2008;. 18:250-6.Search in Google Scholar

17. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology. 1975; 68:627-35.10.1016/S0016-5085(75)80270-8Search in Google Scholar

18. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful, magic, or unnecessary toys?. Gut. 2006; 55:426-31.10.1136/gut.2005.069476Open DOISearch in Google Scholar

19. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV Jr, Harmsen WS, et al. Quantitative measurement and visual assessment of ileal Crohn’s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut. 2006; 55:1561-7.10.1136/gut.2005.084301Open DOISearch in Google Scholar

20. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006; 55:426-31.10.1136/gut.2005.069476Open DOISearch in Google Scholar

21. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982; 12:351-9.10.1111/j.1365-2362.1982.tb02244.xOpen DOISearch in Google Scholar

22. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for infl ammatory bowel disease. Inflamm Bowel Dis. 2004; 10:661-5.10.1097/00054725-200409000-00026Open DOISearch in Google Scholar

23. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical signifi cance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J Clin Gastroenterol. 1988; 10:401-5.10.1097/00004836-198808000-00011Open DOISearch in Google Scholar

24. Shine B, Berghouse L, Jones JE, Landon J. Creactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta. 1985; 148:105-9.10.1016/0009-8981(85)90219-0Open DOISearch in Google Scholar

25. Filik L, Dagli U, Ulker A. C-reactive protein and monitoring the activity of Crohn’s disease. Adv Ther. 2006; 23:655-62.10.1007/BF0285005417050508Open DOISearch in Google Scholar

26. Koelewijn CL, Schwartz MP, Samsom M, Oldenburg B. C-reactive protein levels during a relapse of Crohn’s disease are associated with the clinical course of the disease. World J Gastroenterol. 2008; 14:85-9.10.3748/wjg.14.85267339718176967Open DOISearch in Google Scholar

27. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn’s disease in the presence of a low C-reactive protein. Scand J Gastroenterol. 2006; 41:306-11.10.1080/0036552050021711816497618Open DOISearch in Google Scholar

28. Cavanaugh J. NOD2: Ethnic and geographic differences. World J Gastroenterol. 2006; 12:3673-7.10.3748/wjg.v12.i23.3673Open DOISearch in Google Scholar

29. Amarapurkar DN, Patel ND, Rane PS. Diagnosis of Crohn’s disease in India where tuberculosis is widely prevalent. World J Gastroenterol. 2008; 14: 741-6.10.3748/wjg.14.741Open DOISearch in Google Scholar

30. Balachandar V, Lakshman Kumar B, Sasikala K, Manikantan P, Sangeetha R, Mohana Devi S. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients. J Zhejiang Univ Sci. 2007; B 8: 638-46.10.1631/jzus.2007.B0638Open DOISearch in Google Scholar

31. Mendoza J.L, Murillo L.S, Fernandez L, Pena A.S, Lana R, Urcelay E, et al. Prevalence of mutations of the NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn’s disease. Scand J Gastroenterol. 2003; 38:1235-40.10.1080/00365520310006612Open DOISearch in Google Scholar

32. Cavanaugh JA, Adams KE, Quak EJ, Bryce ME, O’Callaghan NJ, Rodgers HJ, et al. CARD15/NOD2 risk alleles in the development of Crohn’s disease in the Australian population. Ann Hum Genet. 2003; 67: 35-41.10.1046/j.1469-1809.2003.00006.xOpen DOISearch in Google Scholar

33. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterol. 1976; 70:439-44.10.1016/S0016-5085(76)80163-1Search in Google Scholar

34. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterol. 2002; 123:86-91.10.1053/gast.2002.3415512105836Open DOISearch in Google Scholar

35. Lee Y.J, Han Y, Lu H.T, Nguyen V, Qin H, Howe P.H, Hocevar B.A, Boss J.M, Ransohoff R.M, Benveniste E.N (1997). TGF-beta suppresses IFN-gamma induction of class II MHC geneexpression by inhibiting class II transactivator messenger RNA expression. J Immunol. 1997; 158:2065-75.Search in Google Scholar

36. Sandborn WJ, Colombel JF, Enns R, et al. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005; 353: 1912-25.10.1056/NEJMoa04333516267322Search in Google Scholar

37. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005; 129:807-18.10.1053/j.gastro.2005.06.06416143120Open DOISearch in Google Scholar

38. Kaur P, Sambyal V. Lymphocytic chromosomal instability in sporadic gastrointestinal tract cancer patients and their first-degree relatives. Int J Hum Genet. 2008; 8:335-42.10.1080/09723757.2008.11886049Search in Google Scholar

39. Chen Y, Tzengb C, Lioub C, Changb M, Lib C, Linb C. Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors. J Biomed Sci. 2004; 11:65-71.10.1007/BF02256550Open DOISearch in Google Scholar

40. Rossner P, Boffetta P, Capp M, Bonassi S, Smerhovsky Z, Landa K, et al. Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer. Environ Hlth Persp 2005; 113:517-20.10.1289/ehp.6925Open DOISearch in Google Scholar

41. El-Zein R, Gu Y, Sierra MS, Spitz MR, Strom SS. Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14:748-52.10.1158/1055-9965.EPI-04-0236Open DOISearch in Google Scholar

42. Boffetta P, Vander Hel O, Norppa H, Fabianova E, Fucic A, Gundy S, et al. Chromosomal aberrations and cancer risk. Results of a cohort study from central Europe. Am J Epidemio. 2007; 165:36-43.10.1093/aje/kwj367Open DOISearch in Google Scholar

43. Ghosh P, Banerjee M, Chaudhari S, Das JK, Sarma N, Basu A,Giri AK. Increased chromosome aberration frequencies in Bowen’s patients compared to noncancerous skin lesions in individuals exposed to arsenic. Mutat Res. 2007; 632:104-10.10.1016/j.mrgentox.2007.05.005Search in Google Scholar

44. Barletta C, Scillato F, Sega FM, Mannella E. Genetic alteration in gastrointestinal cancer: a molecular and cytogenetic study. Anticancer Res. 1993; 13:2325-9.Search in Google Scholar

45. Dave BJ, Hopwood VL, Hughes JI, Mellilo D, Jackson GL, Pathak S. Nonrandom chromosomal abnormalities in lymphocyte cultures of individuals with colorectal polyps and of asymptomatic relatives of patients with colorectal cancer or polyps. Int J Radiat Biol. 1995; 68:429-35.Search in Google Scholar

46. Sokova OI, Krichenko OP, Kulagina OE, Konstantinova LN, Chebotarev AN, Fleishman EV. Karyotypic anomalies and chromosomal sites of increased fragility in colorectal cancer. Genetika. 1997; 33: 1297-302.Search in Google Scholar

47. Rosenblum-Vos LS, Meltzer SJ, Cox JL, Schwartz S. Cytogenetic studies of primary culture of esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 1993; 70:127-31.10.1016/0165-4608(93)90182-LOpen DOISearch in Google Scholar

48. Calistus Jude AL, Sasikala K, Chandrasekar TS, Ashok Kumar R, Sudha S, Vimala Devi M, et al. Cytogenetic findings in cancerous and non-cancerous lesions of the digestive System. Int J Hum Genet. 2005; 5:199-203.10.1080/09723757.2005.11885926Search in Google Scholar

49. Knudtzon J, Svane S. Turner’s syndrome associated with chronic inflammatory bowel disease. A case report and review of the literature. Acta Med Scand. 1988; 223:375-8.10.1111/j.0954-6820.1988.tb15887.xSearch in Google Scholar

50. Richard F, Muleris M, Dutrillaux B. Chromosome instability in lymphocytes from patients affected by or genetically predisposed to colorectal cancer. Cancer Genet Cytogenet. 1994; 73:23-32.10.1016/0165-4608(94)90178-3Open DOISearch in Google Scholar

51. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterol. 2003; 124:521-36.10.1053/gast.2003.5004512557156Open DOISearch in Google Scholar

52. Pugazhendhi S, Amte A, Balamurugan R, Subramanian V, Ramakrishna BS. Common NOD2 mutations are absent in patients with Crohn’s disease in India. Indian J Gastroenterol. 2008; 27:201-3.Search in Google Scholar

53. Thia KT, Loftus EV, Sandborn WJ and Yang Suk-Kyun. An update on the Epidemiology of Inflammatory Bowel Disease in Asia. Am J Gastroenterol. 2008; 103: 3167-82.10.1111/j.1572-0241.2008.02158.x19086963Open DOISearch in Google Scholar

54. Niriella MA, De Silva AP, Dayaratne AH, Ariyasinghe MH, Navarathne MM, Peiris RS, et al. Prevalence of inflammatory bowel disease in two districts of Sri Lanka: a hospital based survey. BMC Gastroenterol. 2010; 10:32-9.10.1186/1471-230X-10-32285652220302651Open DOISearch in Google Scholar